Timing of chemotherapy start in metastatic pancreatic cancer
Compares starting chemotherapy right away versus later in people with metastatic pancreatic cancer.
Plain-language title generated from the registry record
Registry title: Timing of start of systemlc treatment for asymptomatic MEtastasized PANcreatic cancer (TIMEPAN): a prospective multicenter patient preference cohort
Key facts
- Where
- 'S-Hertogenbosch, Amersfoort, Amsterdam, Enschede, Harderwijk, Hoofddorp, Hoorn Nh, Leiden, Maastricht, Rotterdam, and Utrecht, NetherlandsSee the 12 sites
- Phase
- Phase 3
Where in Netherlands
- Jeroen Bosch Ziekenhuis Stichting'S-Hertogenbosch, NetherlandsTaking people
- Meander Medisch CentrumAmersfoort, NetherlandsTaking people
- Amsterdam UMC StichtingAmsterdam, NetherlandsTaking people
- Medisch Spectrum TwenteEnschede, NetherlandsTaking people
- Ziekenhuis St JansdalHarderwijk, NetherlandsTaking people
- Spaarne Gasthuis StichtingHoofddorp, NetherlandsTaking people
- Dijklander ZiekenhuisHoorn Nh, NetherlandsTaking people
- Leids Universitair Medisch Centrum (LUMC)Leiden, NetherlandsTaking people
- Academisch Ziekenhuis MaastrichtMaastricht, NetherlandsTaking people
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsTaking people
- Diakonessenhuis StichtingUtrecht, NetherlandsTaking people
- St Antonius ZiekenhuisUtrecht, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Amsterdam UMC
- Trial code
- NCT04897854EU 2023-509465-20-00
- Record updated
- 27 October 2026
- Original description
To assess the effect of immediate versus delayed start of chemotherapy on quality adjusted overall survival in patients with metastatic pancreatic cancer.Read full original descriptionShow less
TIming of start of systemIc treatment for asymptomatic MEtastasized PANcreatic cancer (TIMEPAN): a prospective multicenter patient preference cohort
To assess the effect of immediate versus delayed start of chemotherapy on quality adjusted overall survival in patients with metastatic pancreatic cancer.
Inclusion: Signed, written Institutional Review Board/Ethics Committee-approved Informed Consent Form (ICF); No prior chemotherapy for metastatic disease (patients might have received adjuvant treatment more than 3 months before the development of metastatic disease, or neoadjuvant treatment before surgery for resectable disease); Patients with histologically/cytological confirmed diagnosis of metastatic pancreatic ductal adenocarcinoma or MDO consensus of metastatic disease. ; Measurable disease on computed tomography (CT) scan per RECIST version 1.1 criteria; Eastern Cooperative Oncology Group Performance Status of 0-1; Life expectancy ≥ 3 months; Age ≥ 18 years; A negative urine or serum pregnancy test within 7 days before Day 1 (first dose of study medication) if female subject is of childbearing potential; Screening clinical laboratory values as follows: a. Absolute neutrophil count > 1.5 x 109 /L; b.Total bilirubin ≤ 1.5 times upper limit of normal (ULN).; c. Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 times ULN, (if liver metastases are present, then ≤ 5 times ULN is allowed); d.Serum creatinine < 1.5 x ULN or creatinine clearance >50 mL/min/1.73 m2; e. Platelet count > 100,000 x 109 /L; No symptoms related to advanced disease, specified as: a. no pain requiring regular narcotic analgesics; b. no weight loss over 5 kg (unless related to surgery or other illness); c. no persistent nausea requiring medication; d. no obstructive bowel symptoms; e. no persistent fever related to metastatic cancer; f. no other symptom which in the opinion of the clinician was due to progressive metastatic cancer.
Exclusion: New York Heart Association Class III or IV cardiac disease or myocardial infarction within the past 12 months; Any other disease, active, uncontrolled bacterial, viral or fungal infection requiring systemic therapy, metabolic dysfunction, physical examination finding or clinical laboratory finding that leads to reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, that may affect the interpretation of the results, or that may render the subject at high risk for treatment complications; Known central nervous system involvement or brain metastases; Inability to comply with study and follow-up procedures as judged by the Investigator; Women currently pregnant or breastfeeding.